RESUMEN
Estrogen receptor-positive breast cancer patients have a good prognosis, but 30% of these patients will experience recurrence due to the development of resistance through various signaling pathways. This study aimed to evaluate the mode of anticancer effects of 1'-acetoxychavicol acetate, which is isolated from the rhizomes of Alpinia galanga in estrogen receptor positive (MCF7) human epidermal growth factor receptor 2-overexpressed (MCF7/HER2), and endocrine-resistant breast cancer cells (MCF7/LCC2 and MCF7/LCC9). 1'-Acetoxychavicol acetate showed antiproliferation in a concentration- and time-dependent fashion and had higher potency in human epidermal growth factor receptor 2-overexpressed cell lines. This was associated with down-regulation of human epidermal growth factor receptor 2, pERK1/2, pAKT, estrogen receptor coactivator, cyclin D1, and MYC proto-oncogene while in vivo and significant reduction in the tumor mass of 1'-acetoxychavicol acetate-treated zebrafish-engrafted breast cancer groups. The anti-invasive effects of 1'-acetoxychavicol acetate were confirmed in vitro by the matrigel invasion assay and with down-regulation of Câ-âX-C chemokine receptor type 4, urokinase plasminogen activator, vascular endothelial growth factor, and basic fibroblast growth factor 2 genes. The down-regulation of urokinase plasminogen activator and fibroblast growth factor 2 proteins was also validated by molecular docking analysis. Moreover, 1'-acetoxychavicol acetate-treated cells exhibited lower expression levels of the anti-apoptotic Bcl-2 and Mcl-1 proteins in addition to enhanced stress-activated kinases/c-Jun N-terminal kinase 1/2 and poly-ADP ribose polymerase cleavage, indicating apoptotic cell induction by 1'-acetoxychavicol acetate. Moreover, 1'-acetoxychavicol acetate had higher potency in human epidermal growth factor receptor 2-overexpressed cell lines regarding its inhibition on human epidermal growth factor receptor 2, pAKT, pERK1/2, PSer118, and PSer167-ERα proteins. Our findings suggest 1'-acetoxychavicol acetate mediates its anti-cancer effects via human epidermal growth factor receptor 2 signaling pathway.
Asunto(s)
Alpinia , Apoptosis , Alcoholes Bencílicos/farmacología , Neoplasias de la Mama , Alpinia/química , Animales , Neoplasias de la Mama/tratamiento farmacológico , Proliferación Celular , Femenino , Humanos , Células MCF-7 , Simulación del Acoplamiento Molecular , Transducción de Señal , Pez CebraRESUMEN
In carcinomas, the nature of CD40 ligand shapes the outcome of CD40 ligation. To date, the consequences of membrane-bound CD40L (mCD40L) on its immune-stimulatory function are unknown. Here, we examined the impact of mCD40L versus soluble CD40L (sCD40L) on T24 bladder carcinoma gene expression profiling. Of 410 differentially expressed genes, 286 were upregulated and 124 downregulated by mCD40L versus sCD40L. Gene ontology enrichment analysis revealed immune-stimulatory function as the most significant enriched biological process affected by upregulated transcripts, while those downregulated were critical for cell growth and division. Furthermore, immature dendritic cells (iDC) responded to mCD40L with enhanced maturation and activation over sCD40L evidenced by higher expression levels of CD83, CD86, HLA-DR and CD54, increased secretion of IL12 and IL10 and higher tumour-antigen (TA) uptake capacity. Furthermore, autologus CD3+ T cells responded to TA-loaded mCD40L-activated DC with increased proliferation and cytotoxic response (CD107a and IFN-γ-producing CD3+ CD8+ T cells) to the tumour-loaded autologous PBMCs compared to sCD40L. Thus, these data indicate that mCD40L enhances the immunostimulatory capacity over sCD40L. Furthermore, the ability of mCD40L to also directly induce cell death in CD40-expressing carcinomas, subsequently releasing tumour-specific antigens into the tumour microenvironment highlights the potential for mCD40L as a multi-faceted anti-cancer immunotherapeutic.
Asunto(s)
Ligando de CD40/metabolismo , Membrana Celular/metabolismo , Linfocitos T/inmunología , Antígenos CD/metabolismo , Antígenos de Neoplasias/metabolismo , Apoptosis/efectos de los fármacos , Antígenos CD40/metabolismo , Ligando de CD40/genética , Ligando de CD40/farmacología , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Línea Celular Tumoral , Proliferación Celular , Células Dendríticas/citología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Vectores Genéticos/genética , Vectores Genéticos/metabolismo , Humanos , Inmunoglobulinas/metabolismo , Interferón gamma/metabolismo , Interleucina-10/metabolismo , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Glicoproteínas de Membrana/metabolismo , Linfocitos T/citología , Linfocitos T/metabolismo , Neoplasias de la Vejiga Urinaria/inmunología , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/patología , Antígeno CD83RESUMEN
Despite advances in management, bladder cancer remains a major cause of cancer related complications. Characterisation of gene expression patterns in bladder cancer allows the identification of pathways involved in its pathogenesis, and may stimulate the development of novel therapies targeting these pathways. Between 2004 and 2005, cystoscopic bladder biopsies were obtained from 19 patients and 11 controls. These were subjected to whole transcript-based microarray analysis. Unsupervised hierarchical clustering was used to identify samples with similar expression profiles. Hypergeometric analysis was used to identify canonical pathways and curated networks having statistically significant enrichment of differentially expressed genes. Osteopontin (OPN) expression was validated by immunohistochemistry. Hierarchical clustering defined signatures, which differentiated between cancer and healthy tissue, muscle-invasive or non-muscle invasive cancer and healthy tissue, grade 1 and grade 3. Pathways associated with cell cycle and proliferation were markedly upregulated in muscle-invasive and grade 3 cancers. Genes associated with the classical complement pathway were downregulated in non-muscle invasive cancer. Osteopontin was markedly overexpressed in invasive cancer compared to healthy tissue. The present study contributes to a growing body of work on gene expression signatures in bladder cancer. The data support an important role for osteopontin in bladder cancer, and identify several pathways worthy of further investigation.
Asunto(s)
Carcinoma/genética , Regulación Neoplásica de la Expresión Génica , Terapia Molecular Dirigida , Osteopontina/metabolismo , Neoplasias de la Vejiga Urinaria/genética , Anciano , Anciano de 80 o más Años , Biopsia , Carcinoma/tratamiento farmacológico , Carcinoma/metabolismo , Carcinoma/patología , Ciclo Celular , Proliferación Celular , Análisis por Conglomerados , Vía Clásica del Complemento/genética , Cistoscopía , Regulación hacia Abajo , Femenino , Perfilación de la Expresión Génica , Humanos , Inmunohistoquímica , Masculino , Análisis por Micromatrices , Persona de Mediana Edad , Clasificación del Tumor , Transducción de Señal , Transcriptoma , Regulación hacia Arriba , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/patología , Urotelio/patologíaRESUMEN
BACKGROUND: CD40 and its ligand (CD40L) play a critical role in co-ordinating immune responses. CD40 is also expressed in lymphoid malignancies and a number of carcinomas. In carcinoma cells the physiological outcome of CD40 ligation depends on the level of receptor engagement with low levels promoting cell survival and high levels inducing cell death. The most profound induction of cell death in carcinoma cells is induced by membrane-bound rather than recombinant soluble CD40L, but like other TNF family ligands, it is cleaved from the membrane by matrix metalloproteinases. RESULTS: We have generated a replication-deficient adenovirus expressing a mutant CD40L that is resistant to metalloproteinase cleavage such that ligand expression is retained at the cell membrane. Here we show that the mutated, cleavage-resistant form of CD40L is a more potent inducer of apoptosis than wild-type ligand in CD40-positive carcinoma cell lines. Since transgene expression via replication-deficient adenovirus vectors in vivo is low, we have also engineered a conditionally replicating E1A-CR2 deleted adenovirus to express mutant CD40L, resulting in significant amplification of ligand expression and consequent enhancement of its therapeutic effect. CONCLUSIONS: Combined with numerous studies demonstrating its immunotherapeutic potential, these data provide a strong rationale for the exploitation of the CD40-CD40L pathway for the treatment of solid tumours.
Asunto(s)
Adenoviridae/fisiología , Apoptosis , Ligando de CD40/metabolismo , Metaloproteasas/metabolismo , Neoplasias/patología , Replicación Viral/fisiología , Adenoviridae/efectos de los fármacos , Secuencia de Aminoácidos , Apoptosis/efectos de los fármacos , Ligando de CD40/química , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Proliferación Celular/efectos de los fármacos , Humanos , Metaloproteasas/antagonistas & inhibidores , Datos de Secuencia Molecular , Mutación/genética , Inhibidores de Proteasas/farmacología , Replicación Viral/efectos de los fármacosRESUMEN
The effects of CD40 ligation in an epithelial context are complex, with the level of CD40 engagement influencing the physiological outcome. Low levels of CD40 ligation promote cell survival/proliferation, whereas high levels induce growth arrest/apoptosis. The precise form of the CD40 stimulus affects these responses with the most profound effects in carcinoma cells being induced by membrane-bound rather than recombinant soluble CD40L. However, the signaling pathways underlying these differential responses are yet to be fully characterized. We have investigated the mechanistic differences resulting from CD40 engagement by soluble and membrane-bound ligands using a novel adenovirus-delivered CD40L mutated to resist cleavage from the cell membrane in the CD40-positive EJ bladder carcinoma cell line. We have shown that membrane-bound CD40L induces apoptosis by influencing the balance between apoptotic and survival signals. Thus, membrane-bound CD40L stabilizes TNFR-associated factor 3 to induce JNK-dependent apoptosis via release of mitochondrial cytochrome c, caspase 9, and effector caspases 3/7. Further, we have shown that this process is dependent on activation of caspase 8. However, there is also a requirement for suppression of TNFR-associated factor 6-mediated PI3K/Akt-dependent survival signals for apoptosis to occur. These data provide mechanistic insights into the consequences of CD40 activation in carcinoma cells and how these might be exploited in the clinical development of CD40-targeted anticancer therapies.